Provided by Tiger Trade Technology Pte. Ltd.

Xenetic Biosciences Inc

2.77
+0.310012.60%
Post-market: 2.66-0.1126-4.06%19:42 EDT
Volume:414.43K
Turnover:1.05M
Market Cap:6.49M
PE:-2.33
High:2.80
Open:2.50
Low:2.30
Close:2.46
52wk High:13.93
52wk Low:1.87
Shares:2.34M
Float Shares:1.95M
Volume Ratio:0.90
T/O Rate:21.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1900
EPS(LYR):-1.5800
ROE:-47.04%
ROA:-26.80%
PB:1.07
PE(LYR):-1.75

Loading ...

Top Midday Decliners

MT Newswires Live
·
Sep 17

Xenetic, Santerus enter definitive share exchange agreement

TIPRANKS
·
Sep 16

Xenetic Biosciences: Santersus Shareholders to Own About 85% of Combined Co Post-Closing - SEC Filing

THOMSON REUTERS
·
Sep 16

Xenetic Biosciences Agrees to Acquire Santersus in All-Stock Share Exchange Deal

Reuters
·
Sep 16

Xenetic Biosciences Inc: Deal Expected to Create NASDAQ-Listed, Multi-Indication Clinical-Stage Co

THOMSON REUTERS
·
Sep 16

Xenetic Biosciences Inc: Co & Santersus Ag Announce Definitive Share Exchange Agreement

THOMSON REUTERS
·
Sep 16

Xenetic Biosciences: Combined Co Expected to Continue to Trade on NASDAQ Capital Market as Santersus Bio, Inc. Under New Ticker Symbol "Snts"

THOMSON REUTERS
·
Sep 16

NASDAQ Trade Halt Halt News Pending at 06:55 Am

Reuters
·
Sep 16

Xenetic Biosciences Q2 Royalty Revenue Rises on Takeda Sublicense

Reuters
·
Aug 07

Xenetic Biosciences Q2 Net Income USD -900 Thousand

THOMSON REUTERS
·
Aug 07

Xenetic Biosciences Q2 FY26 Net Loss Widens 35% to $929,695; Revenue Rises 12% to $660,601

Reuters
·
Aug 07

Xenetic partner wins Israeli health ministry clearance for DNase I plus anti-CD19 CAR-T lymphoma study

Reuters
·
Jun 04

Xenetic announces preclinical data on DNase I at ASCO

TIPRANKS
·
Jun 01

Xenetic Biosciences posts ASCO 2026 data showing DNase I boosts CAR-T persistence in B-cell cancer models

Reuters
·
Jun 01

Xenetic Biosciences Q1 Net Income USD -500 Thousand

THOMSON REUTERS
·
May 13

Xenetic Biosciences Q1 net loss narrows 49.5% to $456,382

Reuters
·
May 13

Xenetic grants interim CEO, CFO James Parslow 100,000 restricted shares

Reuters
·
Apr 25

Xenetic abstract on DNase I boosting CAR-T efficacy accepted for ASCO presentation

Reuters
·
Apr 22